Abstract
Background and aims: Discrimination in research of new drugs for older people is frequent. We examined research protocols submitted to a research ethics committee, to ascertain whether they stipulated unjustified upper age limits, and whether these age limits are changing in time. Methods: Systematic review of protocols of studies submitted to the Research Ethics Committee of a public university hospital, in four different years, looking for unjustified upper age limits. Studies that dealt with topics or conditions that automatically excluded older people were not examined. Results: In the first three cohorts of protocols of intervention studies (1994, 1999, 2004), 36% to 40% stipulated an upper age limit. In 2007, only 19% of the protocols showed an unjustified limit. Non-intervention trials rarely had upper age limits. Age limits were arbitrarily chosen (65, 70, 75 or 80 years were chosen as cut-off points in most cases). Five to 6% of the protocols specifically concerned older persons, with no change in time. Conclusions: Unjustified age limits are frequent in the protocols of intervention studies, although the numbers have been falling recently. Ethics research committees are in a strong position to influence research practice and to reduce unethical age discrimination.
Similar content being viewed by others
References
Bowling A. Ageism in cardiology. BMJ 1999; 319: 1353–5.
Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997; 315: 1059.
Bartlett C, Doyal L, Ebrahim S et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005; 9: iii–iv, ix–x, 1–152.
Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ 2000; 321: 992–3.
Cruz-Jentoft AJ, Gutiérrez B. Unjustified exclusion of elderly people from clinical research. J Nutr Health Aging 2001; 5 (Suppl): 20 (Abstract).
European Medicines Agency (EMEA). Note for Guidance on Studies in Support of Special Populations: Geriatrics (online). Available at: http://www.emea.europa.eu/pdfs/human/ich/037995en.pdf. Accessed March 21, 2010.
European Medicines Agency Committee for Human Medicinal Products (CHMP). Adequacy of Guidance on the Elderly regarding Medicinal Products for Human Use. EMEA/498920/2006 (online). Available at:http://www.emea.europa.eu/pdfs/human/opiniongen/49892006en.pdf. Accessed March 21, 2010.
Habicht DW, Witham MD, McMurdo ME. The under-representation of older people in clinical trials: barriers and potential solutions. J Nutr Health Aging 2008; 12: 194–6.
Van Spall HG, Toren A, Kiss A et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297: 1233–40.
Avom J. Including elderly people in clinical trials. BMJ 1997; 315: 1033–4.
Godlovitch G. Age discrimination in trials and treatment: old dogs and new tricks. Monash Bioeth Rev 2003; 22: 66–77.
Le Quintrec JL, Bussy C, Golmard JL et al. Randomized controlled drug trials on very elderly subjects: descriptive and methodological analysis of trials published between 1990 and 2002 and comparison with trials on adults. J Gerontol A Biol Sci Med Sci 2005; 60: 340–4.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cruz-Jentoft, A.J., Gutiérrez, B. Upper age limits in studies submitted to a research ethics committee. Aging Clin Exp Res 22, 175–178 (2010). https://doi.org/10.1007/BF03324793
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03324793